January 3, 2019
December 13, 2018
Retrotope Announces First Dosing of RT001 in patients with Infantile Neuroaxonal Dystrophy (INAD)
October 17, 2018
Immusoft Receives Rare Pediatric Disease Designation For Treatment Of MPS I
October 3, 2018
VelosBio raises $58M in Series A round for antibody-drug conjugate development
September 12, 2018
Oncternal Announces First Patient Dosed in Phase 1b Clinical Trial of Cirmtuzumab in Combination with Paclitaxel in Patients with Breast Cancer
July 24, 2018
Nabriva Therapeutics Strengthens Antibiotics Leadership Position with Acquisition of Zavante Therapeutics
July 10, 2018
Jason Fontenot, Ph.D., Joins Immusoft As Chief Scientific Officer
July 9, 2018
Retrotope Announces Publication of Preclinical Research Showing Cognitive Improvements in a Huntington’s Disease Model Using Deuterated Polyunsaturated Fatty Acid (D-PUFA) Drug Candidate
June 1, 2018
Oncternal Announces Publication of Data from Phase 1 Trial of Cirmtuzumab in CLL in Cell Stem Cell
May 3, 2018